More About Jorge
Jorge Conde is a General Partner on the Bio + Health team, where he focuses on life sciences and healthcare investments across therapeutics, diagnostics, tools, and software. Jorge currently serves on the boards of Asimov, CAMP4, Cartography, Dyno, Earli, EQRx, IDRx, Komodo Health, Octant Bio, and Vicinitas.
Prior to joining Andreessen Horowitz, Jorge served as Chief Strategy Officer, Chief Financial Officer, and Chief Product Officer for Syros. Jorge was also cofounder and Chief Executive Officer of Knome, a human genome interpretation company acquired by Tute Genomics in 2015. Before that, Jorge worked in marketing and operations at MedImmune and as a biotechnology investment banker at Morgan Stanley.
Jorge holds an MBA from Harvard Business School, an MS from the Harvard-MIT Division of Health Sciences and Technology, and a BA in biology from Johns Hopkins University. Jorge was named one of the top 35 young innovators in the world by the MIT Technology Review and is a Henry Crown Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. He previously served on the board of the Museum of Science, Boston.
Born and raised in Miami by Cuban and Peruvian parents, and married to a Madrileña, Jorge and his family of six live in California. The family cheers for Real Madrid, the Boston Red Sox, and the Miami Dolphins.
Featured Content
-
As we strive to find and support the most ambitious life sciences founders, we also work to connect these founders with exceptional advisors who have traveled the journey before.
-
In this episode, Jorge Conde, general partner at a16z Bio + Health, talks with Josh Mandel-Brehm, founding CEO of CAMP4.
-
with @rvenkayya @jorgecondebio @smc90 As with all of the episodes on this show about tech & science trends in the news, and where they are on the long arc of innovation — this one is actually a story of human i...
-
Eroom’s Law (the backwards Moore) is the often cited, and arguably inaccurate, observation that drug discovery gets slower and more expensive over time. It’s certainly a slog, but R&D efforts have yielded 378 new...
-
Kevin Parker, cofounder and CEO of Cartography Biosciences, joins Jorge Conde, general partner at a16z Bio + Health, and Olivia Webb, editorial lead.
Select Investments
Any investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments. A list of investments made by funds managed by a16z is available here: https://a16z.com/investment-list/.
